A recombinant allergen chimer as novel mucosal vaccine candidate for prevention of multi‐sensitivities

Background:  As conventional immunotherapy is less efficacious in patients with allergic multi‐sensitivities compared with mono‐sensitized subjects, new intervention strategies are needed. Therefore, an allergen chimer was genetically engineered for treatment of multi‐sensitization with birch and grass pollen on the basis of mucosal tolerance induction.

[1]  E. Kallay,et al.  The role of Foxp3+ T cells in long‐term efficacy of prophylactic and therapeutic mucosal tolerance induction in mice , 2006, Allergy.

[2]  Rudolf Valenta,et al.  Molecular design of allergy vaccines. , 2005, Current opinion in immunology.

[3]  R. Clynes,et al.  Cell surface recycling of internalized antigen permits dendritic cell priming of B cells. , 2005, Immunity.

[4]  C. Akdis,et al.  Prevention of allergy by a recombinant multi‐allergen vaccine with reduced IgE binding and preserved T cell epitopes , 2005, European journal of immunology.

[5]  U. Wiedermann.  Prophylaxis and therapy of allergy by mucosal tolerance induction with recombinant allergens or allergen constructs. , 2005, Current drug targets. Inflammation and allergy.

[6]  H. Renz,et al.  Intranasal tolerance induction with polypeptides derived from 3 noncross-reactive major aeroallergens prevents allergic polysensitization in mice. , 2005, The Journal of allergy and clinical immunology.

[7]  C. Akdis,et al.  A major allergen gene-fusion protein for potential usage in allergen-specific immunotherapy. , 2005, The Journal of allergy and clinical immunology.

[8]  A. Mowat,et al.  Induction of Bystander Suppression by Feeding Antigen Occurs despite Normal Clonal Expansion of the Bystander T Cell Population1 , 2004, The Journal of Immunology.

[9]  B. Bohle,et al.  Influence of the route of sensitization on local and systemic immune responses in a murine model of type I allergy , 2004, Clinical and experimental immunology.

[10]  P. Norman.  Immunotherapy: 1999-2004. , 2004, The Journal of allergy and clinical immunology.

[11]  C. Radauer,et al.  Lab scale and medium scale production of recombinant allergens in Escherichia coli. , 2004, Methods.

[12]  G. Canonica,et al.  Sublingual immunotherapy: an update , 2004, Current opinion in allergy and clinical immunology.

[13]  C. Ebner,et al.  Allergen‐specific immunosuppression by mucosal treatment with recombinant Ves v 5, a major allergen of Vespula vulgaris venom, in a murine model of wasp venom allergy , 2003, Immunology.

[14]  K. Hoffmann‐Sommergruber,et al.  Cloning and Molecular and Immunological Characterisation of Two New Food Allergens, Cap a 2 and Lyc e 1, Profilins from Bell Pepper (Capsicum annuum) and Tomato (Lycopersicon esculentum) , 2003, International Archives of Allergy and Immunology.

[15]  M. Jenmalm,et al.  Total and allergen‐specific immunoglobulin A levels in saliva in relation to the development of allergy in infants up to 2 years of age , 2002, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[16]  R. Valenta,et al.  The FASEB Journal express article 10.1096/fj.01-1012fje. Published online June 21, 2002. , 2022 .

[17]  H. Breiteneder,et al.  Genetic Engineering of Allergens: Future Therapeutic Products , 2002, International Archives of Allergy and Immunology.

[18]  R. Valenta.  The future of antigen-specific immunotherapy of allergy , 2002, Nature Reviews Immunology.

[19]  B. Wüthrich,et al.  Different methods of local allergen‐specific immunotherapy , 2002, Allergy.

[20]  P. Briza,et al.  Molecular and Immunological Characterization of Profilin from Mugwort Pollen , 2002, Biological chemistry.

[21]  H. Eichler,et al.  Mucosal tolerance as therapy of type I allergy: intranasal application of recombinant Bet v 1, the major birch pollen allergen, leads to the suppression of allergic immune responses and airway inflammation in sensitized mice , 2002, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[22]  R. Valenta,et al.  Intranasal Treatment with a Recombinant Hypoallergenic Derivative of the Major Birch Pollen Allergen Bet v 1 Prevents Allergic Sensitization and Airway Inflammation in Mice , 2001, International Archives of Allergy and Immunology.

[23]  A. Kagey‐Sobotka,et al.  Recombinant Allergens with Reduced Allergenicity but Retaining Immunogenicity of the Natural Allergens: Hybrids of Yellow Jacket and Paper Wasp Venom Allergen Antigen 5s1 , 2001, The Journal of Immunology.

[24]  G. Rossi,et al.  Age-dependent tendency to become sensitized to other classes of aeroallergens in atopic asthmatic children. , 1999, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[25]  H. Renz,et al.  Suppression of antigen-specific T- and B-cell responses by intranasal or oral administration of recombinant bet v 1, the major birch pollen allergen, in a murine model of type I allergy. , 1999, The Journal of allergy and clinical immunology.

[26]  Z. Derewenda,et al.  Overcoming expression and purification problems of RhoGDI using a family of "parallel" expression vectors. , 1999, Protein expression and purification.

[27]  Kahlert,et al.  Mapping of T‐cell epitopes of Phl p 5: evidence for crossreacting and non‐crossreacting T‐cell epitopes within Phl p 5 isoallergens , 1998, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[28]  S. Bonini,et al.  Pollen‐related allergy in Europe * , 1998, Allergy.

[29]  C. Akdis,et al.  Differential regulation of human T cell cytokine patterns and IgE and IgG4 responses by conformational antigen variants , 1998, European journal of immunology.

[30]  J. Lamb,et al.  Characterization of the specificity and duration of T cell tolerance to intranasally administered peptides in mice: a role for intramolecular epitope suppression. , 1997, International immunology.

[31]  H. Weiner,et al.  Dose‐dependent Activation and Deletion of Antigen‐specific T Cells following Oral Tolerance , 1996, Annals of the New York Academy of Sciences.

[32]  J. Lamb,et al.  An immunogenetic analysis of the T-cell recognition of the major house dust mite allergen Der p 2: identification of high- and low-responder HLA-DQ alleles and localization of T-cell epitopes. , 1995, Immunology.

[33]  D. Kraft,et al.  Basic and practical aspects of recombinant allergens , 1995, Allergy.

[34]  H. Weiner,et al.  Antigen-driven bystander suppression after oral administration of antigens , 1991, The Journal of experimental medicine.

[35]  S. Challacombe,et al.  Systemic tolerance and secretory immunity after oral immunization , 1980, The Journal of experimental medicine.

[36]  L. Lichtenstein,et al.  IgA and IgG anti-ragweed antibodies in nasal secretions. Quantitative measurements of antibodies and correlation with inhibition of histamine release. , 1976, The Journal of clinical investigation.

[37]  R. Valenta,et al.  T-cell epitopes of Phl p 1, major pollen allergen of timothy grass (Phleum pratense): evidence for crossreacting and non-crossreacting T-cell epitopes within grass group I allergens. , 1995, The Journal of allergy and clinical immunology.

[38]  M. Breitenbach,et al.  Monoclonal antibodies against birch pollen allergens: characterization by immunoblotting and use for single-step affinity purification of the major allergen Bet v I. , 1989, International archives of allergy and applied immunology.